naltrexone has been researched along with Cholera Infantum in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Acevedo-Mackey, D; Acharjee, N; Akhtar, K; Al-Buriahi, MS; Amandi, A; An, Y; Anjum, NA; Asgari, Q; Badiei, B; Baez Vasquez, AY; Bagley, GD; Bahreini, MS; Bajelan, S; Baluja, MQ; Barbieri, MA; Batalha, MA; Bettiol, H; Bhattarai, U; Biset, JC; Bjerg, M; Björnsson, BT; Boag, AM; Borthwick, MS; Boukhris, I; Bragança, MLBM; Breves, JP; Britz-McKibbin, P; Broaddus, RR; Burnell, JE; Camargo, CA; Campo, M; Carlsen, KL; Catchpole, B; Cavalli, L; Chai, C; Chanakya, HN; Chang, AYH; Chantada, A; Chen, W; Chen, X; Chen, Y; Cheng, ZL; Chenoweth, DA; Chhetri, S; Coelho, CCNDS; Coker, ES; Cole, MA; Coniglio, A; Connor, TR; Corbishley, A; D'Arienzo, M; da Silva, AAM; Dai, Y; de Oliveira, BR; Dignac, MF; Dong, A; Dottino, JA; Duo, J; Einarsdottir, IE; Ekanayake, EMDNK; El Fels, L; El Hayany, B; El Shahawy, O; Elliott, RJR; Fabrizi, E; Farkas, K; Fellman, B; Fenoglio, D; Ferrario, M; Flögel, F; Fujiogi, M; Gamage, BD; Ganson, KT; Gao, X; Gärtner, S; Gautam, A; Gautam, S; Gaze, WH; Gosse, JA; Graham, DW; Graham, PA; Guastella, G; Guerrero, S; Gul, M; Guo, B; Guo, X; Gupta, VK; Hafidi, M; Halland, A; Han, W; Hardisty, M; Hasegawa, K; Hess, ST; Heydari, R; Hillary, LS; Holm, R; Huang, L; Jaleh, B; Jayasundara, JASB; Ji, X; Jiang, L; Jones, DL; Kac, G; Kebaili, I; Kelley, JB; Kelum, SHP; Kennedy, LJ; Khan, NA; Khazalpour, S; Khuntia, HK; Kinney, MS; Kommedal, Ø; Koomhin, P; Krawczyk, N; Kæstel, T; Lakmal, MAC; Li, H; Li, K; Li, R; Li, S; Li, W; Li, X; Li, Y; Liang, L; Lin, Y; Lippo, E; Liu, B; Liu, F; Liu, J; Liu, X; Liu, Y; Lodha, D; Loose, DS; López-Meza, P; Lu, F; Lu, KH; Lu, Y; Luo, Y; Ma, B; Malham, SK; Masood, A; Matan, N; McCormick, SD; McDonald, JE; McKenzie, LJ; Melendez, BD; Mikaeili, F; Mir, IR; Mirjalili, MH; Moreno, KP; Moura, IB; Müller, S; Nagata, JM; Nasri, A; Nasrollahzadeh, M; Navarro-Jiménez, E; Nie, E; Nielsen, CU; Nielsen, S; Nøhr, MK; Obeng, B; Odetayo, AA; Ortiz-Barrios, M; Ozgen, C; Pan, X; Parisi, ML; Paskavitz, AL; Patel, AK; Pedersen, M; Pontarollo, N; Potts, CM; Price, C; Pu, Y; Quénéa, K; Rahimi Khonakdari, M; Rather, BA; Raut, P; Regish, AM; Reible, DD; Rezadoost, H; Rizzati, M; Roviello, GN; Roviello, V; Rumpel, C; Sang, J; Sangroula, S; Saraiva, MDCP; Sarker, A; Sayyed, MI; Segoshi, A; Sehar, Z; Shao, X; Shaw, D; Shaw, L; Shekhawat, NS; Shim, JK; Shokouhimehr, M; Short, A; Soliman, PT; Songsamoe, S; Springer-Miller, RH; Stenstad, T; Strobl, E; Sun, R; Syme, H; Thai, L; Tian, G; Tofighi, B; Tonguc, B; Tuyiringire, D; Ulaganathan, N; Ulvestad, E; Varacca, A; Vergalli, S; Verma, DK; Villmones, HC; Wang, D; Wang, H; Wang, J; Wang, L; Wang, M; Wang, S; Wang, Y; Wang, Z; Weedon-Fekjær, H; Weller, SR; West, BE; Wilcox, MH; Wu, W; Wufuer, R; Xia, S; Xiang, H; Xu, H; Yan, L; Yang, RK; Yang, Y; Yates, MS; Ye, Q; Yin, H; Yin, Y; Yuan, Y; Yucesan, M; Yue, W; Zeng, W; Zhang, C; Zhang, D; Zhang, H; Zhang, L; Zhang, Q; Zhang, Y; Zhou, B; Zhou, Y; Zhu, Y; Zhu, Z | 1 |
| Gibaja, V; Gillet, P; Labroca, P; Lemarié, J; Martini, H; Paille, F; Petitpain, N; Yéléhé-Okouma, M | 1 |
| Fleckenstein, J; Napadow, V; Nowak-Machen, M; Pfab, F | 1 |
| Chapman, MJ; Deane, AM; Nguyen, NQ | 1 |
| Chiao, F; Erice, S; Leverone, T; Ma, H; Pearce, S; Quon, R; Tang, J; Wender, RH; White, PF | 1 |
| Ait-Daoud, N; Aubin, HJ; Ehrich, E; Guzzetta, R; Johnson, BA; Loewy, J; Silverman, B; Van Den Brink, W | 1 |
| Brune, A; Luger, TA; Metze, D; Ständer, S | 1 |
| Carroll, K; Levinson, C; Nich, C; Petrakis, I; Poling, J; Ralevski, E; Rounsaville, B | 1 |
| DeHaven, RN; DeHaven-Hudkins, DL; Little, PJ; Techner, LM | 1 |
| Kranzler, HR; Oncken, C; Van Kirk, J | 1 |
5 review(s) available for naltrexone and Cholera Infantum
| Article | Year |
|---|---|
Topics: Acyclic Monoterpenes; Adipose Tissue; Adolescent; Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollutants, Occupational; Amino Acid Transport Systems; Analgesics, Opioid; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Arthrobacter; Bacteria; Bacteriological Techniques; Benzaldehydes; Biodegradation, Environmental; Biofilms; Biological Transport; Biomarkers; Biomass; Bioreactors; Body Composition; Body Mass Index; Brassica; Brazil; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Caco-2 Cells; Cadmium; Calcium; Calcium Carbonate; Calcium Channels; Catalysis; Cell Degranulation; Cell Line; Cell Membrane; Chitosan; Chromatography, High Pressure Liquid; Chromium; Cobalt; Cohort Studies; Colony Count, Microbial; Composting; Copper; COVID-19; Cross-Sectional Studies; Cytoplasm; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Diethylhexyl Phthalate; Dose-Response Relationship, Drug; Drug Implants; Drug Stability; Drug Synergism; Electroplating; Endometrial Neoplasms; Endometrium; Environmental Monitoring; Environmental Restoration and Remediation; Estradiol; Estrogens; Feces; Female; Food Microbiology; Food Preservation; Fruit and Vegetable Juices; Gasotransmitters; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gene Expression Regulation, Developmental; Genetic Predisposition to Disease; Glutathione; Gold; Graphite; Growth Hormone; Harm Reduction; Hot Temperature; Humans; Hydrocortisone; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydrogen-Ion Concentration; Ileum; Imidazoles; Injections, Intraperitoneal; Insecticides; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 5; Insulin-Like Growth Factor I; Intestinal Absorption; Light; Lignin; Liver; Magnetics; Male; Manganese; Mast Cells; Melanoma; Membrane Potentials; Metals; Methadone; Microbial Viability; Microplastics; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Middle Aged; Mitochondrial Swelling; Molecular Dynamics Simulation; Monophenol Monooxygenase; Morocco; Naloxone; Naltrexone; Nanocomposites; Nanomedicine; Nanoparticles; Narcotic Antagonists; Neonicotinoids; Nitric Oxide; Nitro Compounds; Nitrogen; Nitrogen Compounds; Obesity; Obesity, Abdominal; Occupational Exposure; Ontario; Opiate Substitution Treatment; Opioid-Related Disorders; Oryza; Overweight; Oxidative Stress; Oxides; Oxygen; Perception; Photoelectron Spectroscopy; Plants; Plastics; Point Mutation; Polychlorinated Biphenyls; Polycyclic Aromatic Hydrocarbons; Potassium; Premenopause; Prodrugs; Prospective Studies; Protons; Pyrolysis; Qualitative Research; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Resins, Synthetic; Rhodamines; Risk Factors; ROC Curve; Salmo salar; SARS-CoV-2; Seawater; Severity of Illness Index; Sewage; Social Media; Soil; Soil Microbiology; Soil Pollutants; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Staining and Labeling; Stainless Steel; Steel; Stress, Physiological; Substance Abuse Treatment Centers; Symporters; T-Lymphocytes; Toluene; Triclosan; Ultraviolet Rays; Waist Circumference; Waste Disposal, Fluid; Wastewater; Water Purification; Welding; X-Ray Diffraction; Young Adult | 2020 |
Alternatives to prokinetics to move the pylorus and colon.
Topics: Acupuncture Therapy; Animals; Colon; Complementary Therapies; Enema; Gastrointestinal Agents; Gastrointestinal Diseases; Gastrointestinal Motility; Humans; Laxatives; Naltrexone; Narcotic Antagonists; Piperidines; Probiotics; Pylorus; Quaternary Ammonium Compounds | 2012 |
Gastrointestinal dysmotility: evidence and clinical management.
Topics: Cholecystokinin; Critical Illness; Enteral Nutrition; Evidence-Based Medicine; Gastric Emptying; Gastrointestinal Agents; Gastrointestinal Diseases; Ghrelin; Humans; Intestine, Small; Motilin; Naltrexone; Quaternary Ammonium Compounds; Randomized Controlled Trials as Topic | 2013 |
The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor.
Topics: Analgesics, Opioid; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Naltrexone; Narcotic Antagonists; Piperidines; Quaternary Ammonium Compounds; Receptors, Opioid, mu | 2008 |
Adverse effects of oral naltrexone: analysis of data from two clinical trials.
Topics: Administration, Oral; Adult; Affective Symptoms; Alcoholism; Chi-Square Distribution; Cross-Sectional Studies; Fatigue; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Models, Biological; Models, Psychological; Naltrexone; Narcotic Antagonists; Nausea; Patient Compliance; Secondary Prevention | 2001 |
3 trial(s) available for naltrexone and Cholera Infantum
| Article | Year |
|---|---|
A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence.
Topics: Adult; Alcoholism; Delayed-Action Preparations; Double-Blind Method; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Male; Naltrexone; Pilot Projects | 2004 |
[Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nervous System Diseases; Pruritus; Tachyphylaxis; Treatment Outcome | 2004 |
Naltrexone and disulfiram in patients with alcohol dependence and current depression.
Topics: Alcohol Deterrents; Alcoholism; Bipolar Disorder; Cocaine-Related Disorders; Comorbidity; Connecticut; Depressive Disorder, Major; Disulfiram; Double-Blind Method; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Gastrointestinal Diseases; Humans; Male; Massachusetts; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Stress Disorders, Post-Traumatic; Treatment Outcome; Veterans | 2007 |
3 other study(ies) available for naltrexone and Cholera Infantum
| Article | Year |
|---|---|
Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine.
Topics: Adult; Aged; Alcoholism; Analgesics, Opioid; Female; France; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Pancreatitis; Retrospective Studies; Substance Withdrawal Syndrome | 2017 |
The effect of clonidine on gastrointestinal side effects associated with ultra-rapid opioid detoxification.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Diarrhea; Female; Gastrointestinal Diseases; Humans; Hypnotics and Sedatives; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Nausea; Opioid-Related Disorders; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome; Vomiting | 2003 |
[Antipuritic therapy with naltrexone].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nervous System Diseases; Pruritus; Tachyphylaxis; Treatment Outcome | 2005 |